Substituted anilines as ccr(4) antagonists

A compound having formula (I):

• and any pharmaceutically acceptable salts thereof, wherein
• R1 is a member selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, C3-8 cycloalkyl, halogen, —CN, —SO2Me and —C(O)NH2;
• each R2 is a member selected from the group consisting of C1-8 alkyl, C1-8haloalkyl, halogen, —CN and C1-8 alkoxy;
• or two R2 groups attached to adjacent carbon atoms are optionally connected to foim a 5- or 6-member ring which is optionally substituted with additional R2 groups;
• R3 is a member selected from the group consisting of hydrogen, methyl and C haloalkyl;
• R4 is a member selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl and C1-8 hydroxyalkyl;
• each of the subscripts n is independently an integer from 0 to 3;
• B is a bond or C(O);
• Q is a member selected from the group consisting of C, CH, N, O, S, S(O) and SO2;
• W, X, Y, and Z are independently selected from the group consisting of C, CH and N, but Q and W are not both N;
• R5 and R6 are absent or are members independently selected from the group consisting of H, —OH, C1-8 alkyl, C1-8 hydroxyalkyl, C1-4 alkoxy-C1-4 alkyl, —C(O)NRaRb, C1-8 alkylene-C(O)NRaRb, —NH—C1-4 alkylene-C(O)NRaRb, —C(O)—C1-4 alkylene-NRaRb, —CO2H and acid isosteres, C1-8 alkylene-CO2H and acid isosteres, —N(Ra)C(O)NRaRb, C1-8 alkylene N(Ra)C(O)NRaRb, —NRaRb, C1-8 alkylene-NRaRb, C1-8 alkoxy, —C(O)ORa, C1-8 alkylene-C(O)ORa, —CN, —C(O)Ra, —SO2Ra and —N(Ra)C(O)Rb;
• wherein
• each Ra and Rb are independently selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 hydroxyalkyl, C1-8haloalkyl, and C1-8 alkoxy;
• and
• R7 is absent or is selected from the group consisting of H, C1-8 alkyl and C1-8 haloalkyl.